MERCK, LILLY, MARION LEAD DRUG STOCKS TO BIGGEST GAIN IN NEARLY TWO YEARS
Executive Summary
MERCK, LILLY, MARION LEAD DRUG STOCKS TO BIGGEST GAIN IN NEARLY TWO YEARS Merck (up 6 to 88-1/2), Lilly (up 4-1/2 to 59), and Marion (up 4-3/8 to 39-1/2) led rebounding Pharmaceutical stocks on the "F-D-C" Index to the group's biggest single week gain in almost two years. Overall, 52 of 53 stocks listed on the index advanced -- Cooper fell 7/8 to 21-7/8 -- as the Composite posted its largest single week jump since the August 1982 rally, climbing 7.4% compared with the Dow's 7.8% leap. Other drug stocks leading the charge were SmithKline Beckman (up 4-1/4 to 58-7/8), Abbott (up 2-7/8 to 46-1/4), and Squibb (up 2-7/8 to 47-7/8). Novo (up 6 to 46-3/8) and Pfizer (up 3-1/4 to 35-1/2) were among the Diversified leaders, while Walgreens (up 5-5/8 to 40-1/2) was top for the Chains. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth